ADA

Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of as y...

Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009

Additional Analyses Showed Pramlintide Improved Treatment Satisfaction and Quality of Life NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced data showing that the use of mealtime SYMLIN(R) (pramlintide acetate) injection improved gluc...

Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting

WALTHAM, Mass., June 5 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI ) announced today that Nazneen Aziz, Ph.D., Vice President of Research and Development, will present findings that highlight significant associations between perilipin gene variants and response to weig...

Fora Care Inc. to Launch Cost-Effective Solution for Diabetes Care at ADA 69th Scientific Sessions

NEW ORLEANS, June 4 /PRNewswire/ -- Fora Care announces the launch of their Telehealth Solution for Diabetes Care and the unveiling of their Point of Care Testing (POCT) System at the American Diabetes Association (ADA) 69th Scientific Sessions conference from June 6-8 at the Ernest N. Morial Conv...

Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009

SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced that the company will present data for its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its investigational diabetes drug ca...

Video: ADA 23rd New Dentist Conference: Making Waves in Miami

April 30-May 2, 2009 Hyatt Regency Miami MIAMI, April 16 /PRNewswire/ -- Get Ready to Make Some Waves! The ADA 23rd New Dentist Conference: Making Waves in Miami will be held April 30-May 2, 2009 at the Hyatt Regency in Miami, FL. Join the ADA Committee on the New Dentist for ...

Statement by ADA President John S. Findley on the Dental Emergency Responder Act Introduced Today by Reps. Stupak and Miller

WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- The following is a statement by ADA President John S. Findley: "The American Dental Association commends Reps. Bart Stupak (D-Mich.) and Candice Miller (R-Mich.) for introducing the 'Dental Emergency Responder Act' (H.R. 903), a bill that would bo...

MultiVu Video Feed: ADA Offers Tips For Enjoying Holiday Sweets and Keeping That "Sweet Tooth" Intact

With all the temptation to eat sweets this coming holiday season, the American Dental Association is reminding folks to take good care of their teeth. Those moments of temptation during holiday festivities could lead to tooth decay, gum disease, and possibly tooth loss down the road. The ADA...

Seyfarth Shaw Partner Camille A. Olson, Senate Witness for ADA Amendments Act, Comments on President's Signing of Bill into Law

Seyfarth Shaw LLP, one of America’s leading full-service law firms, today released the following statement from Camille A. Olson, a Senate and House witness who provided testimony on the Americans with Disabilities Act Amendments Act (ADA Amendments Act) and Chair of the national law firm&r...

Essential dental treatment safe for pregnant women, says ADA journal study

CHICAGO, June 10, 2008 Pregnant women can safely undergo essential dental treatment and receive topical and local anesthetics at 13 to 21 weeks gestation, says a study published in the June issue of The Journal of the American Dental Association . Although obstetricians generally consider dent...

More>>

ADA in Medical Technology

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively Assessed in Large Outcomes Trial NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a meta-analysis of ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Improvements in Systolic Blood Pressure and Triglycerides Also Observed NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharma...

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

- Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense SAN FRANCISCO and CARLSBA...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (N...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

Submitted to FDA for Stand-Alone Therapy in Q1 2008 SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced additional results from a study of patients with type 2 diabetes who were unable t...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that data featuring its approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline candidates will be presented at the American Diabetes Ass...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improve...

More>>

ADA in Medical Products

B-VAT® PC CPU

Description:...selection capability. The B-VAT PC also includes a hearing impaired patient communications system that may allow the system to qualify for the Federal ada Tax Credit...
Company:Medtronic

B-VAT® Flat Panel Color Compatible Monitor

Description:...selection capability. The B-VAT PC also includes a hearing impaired patient communications system that may allow the system to qualify for the Federal ada Tax Credit...
Company:Medtronic

B-VAT® PC Software

Description:...selection capability. The B-VAT PC also includes a hearing impaired patient communications system that may allow the system to qualify for the Federal ada Tax Credit...
Company:Medtronic

B-VAT® Compatible Color CRT Monitor

Description:...selection capability. The B-VAT PC also includes a hearing impaired patient communications system that may allow the system to qualify for the Federal ada Tax Credit...
Company:Medtronic

B-VAT® PC Full System

Description:...selection capability. The B-VAT PC also includes a hearing impaired patient communications system that may allow the system to qualify for the Federal ada Tax Credit...
Company:Medtronic

Pach IV

Features:... Portabliity qualifies for ada tax incentive Lightweight 3.0 lbs Accuracy is +/- 5 microns Resolution of +/- 1 micron Angled or straight probe Continuous or foot peta...
Company:Accutome, Inc.

Chemcard Glucose Test

Features:... The ada recommends screening individuals having one or more of the following diabetes risk factors, every three years: Family history of diabetes: Parents ...
Company:Chematics Inc.

More>>

ADA in Medical Dictionary

Synapse

...ol at L-TronDirect.com. Find the industrial products you need at great prices. Provides adaptive and assistive technologies for the disabled user: ada workstations, furniture, library access, voice recognition, display magnification, and more. Synapse ... The Intelligence of Synapse — 1 comme...

Oral hygiene

.... some tips for daily oral care? How do I brush ... Find information here about tooth (tooth brushing) and gum care ( oral hygiene ) ... The ada recommends the following for good oral hygiene : ... Oral hygiene is the practice of keeping the mouth clean and healthy by brushing ... Th...

Oral cancers

...e no other ... This page provides current information on Oral Cancer as it relates to dental professionals. ... Facts About Oral Cancer . ada News. The Journal of the American ... Learn more about oral cancer , including causes, risk factors, symptoms, and treatment. ... Oral cance...

Disability

...ilitation ... ... And Conduct Standards To Employees With Disabilities . Veterans with Service-Connected Disabilities in the Workplace and the ada ... Disability Discrimination ... Details on common disabilities , common disorders, and common diseases that could result in social security ...

Dental caries

...ous disease which damages the structures of teeth. ... There is a long history of dental caries , with evidence showing the disease was ... ada MEMBERS ONLY: This page provides information about the American Dental Association dental practice parameters on Dental Caries , for voluntary ...

Caries

...Tooth Decay (BBTD), others ... bottle nor breast milk predispose to caries . ... Guidelines for a child's oral health are contained in this ada Statement on Early Childhood Caries . ... Early childhood caries is an infectious disease. ... ...

ADH

... hormone ( ADH ), is a hormone found in most mammals, including humans. Vasopressin is a peptide hormone. It is derived from a preprohormone... ada Municipal Airport (FAA LID: ADH ) in Ada, Oklahoma ... Retrieved from "http://en.wikipedia.org /wiki/ ADH " Categories: Disambiguation...

ADA in Biological News

ADA releases updated position paper on vegetarian diets

...se following a varied, balanced vegetarian diet." The position paper draws on results from ADA's evidence analysis process and information from the ada Evidence Analysis Library to show vegetarian diets can be nutritionally adequate in pregnancy and result in positive maternal and infant health outcom...

ADA releases updated position statement on functional foods

... consumed as part of a varied diet on a regular basis, at effective levels. ada supports research to further define the health benefits and risks of indivi...d be based on the significant scientific agreement standard of evidence and ada supports label claims based on such strong scientific substantiation. Food ...

Diabetics on high-fiber diets might need extra calcium, report UT Southwestern researchers

...udy, 13 patients with type 2 diabetes ate either a high-fiber diet (50 grams per day) or the moderate-fiber diet (24 grams per day) recommended by the ada for six weeks, then switched to the other diet for six weeks. All participants stayed at UT Southwestern's Clinical and Translational Research Center ...

American Dietetic Association releases 2008 nutrition trends survey

...onwide consumer opinion survey, Nutrition and You: Trends 2008. In each ada survey since 1991, ada has used respondents' answers to a number of different questions to segment...

Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration

...o pancreatic autoantigens. Clinical Trial Criteria Key inclusion criteria for this trial include: a diagnosis of type 1a diabetes mellitus based on ada criteria, ≤5 years since T1D was diagnosed, ≥ 18 years of age, ≤ 40 years of age at the time of diagnosis of Type 1 diabetes, detect...

News from the October 2008 Journal of the American Dietetic Association

...urces. The American Dietetic Association encourages consumers to consume adequate amounts of fiber, particularly from food sources, according to a new ada position statement published this month on the health implications of dietary fiber: It is the position of The American Dietetic Association that t...

Highlights from the November 2007 Journal of the American Dietetic Association

... to receive a copy of a Journal article, e-mail media@eatright.org . ada Participates in Global Theme Issue on Poverty and Human Development The J...vember issue as open access, meaning that they are freely available to both ada members and non-members alike through the Journals Web site at www.adajourn...

An 'elegant' idea proves its worth 25 years later

...ea was to give patients chemicals they already make in small amounts in large doses to make up for the missing urea cycle enzyme they inherited," says ada Hamosh, M.D., M.P.H, clinical director of the McKusick-Nathans Institute of Genetic Medicine. "Sodium phenylacetate and sodium benzoate already know h...

Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes

...Study began in April 2005 to identify physiological, clinical, genetic and other factors shared by the Medalists. The study being presented at the ada meeting is part of the second phase of the Joslin 50-Year Medalist Study that is assessing these factors in 326 patients with more than 50 years of in...

Living with salt

...salt remained unresolved. In a recent paper published in the Proceedings of the National Academy of Sciences, USA (PNAS), Institute scientists Prof. ada Zamir and Dr. Lakshmanane Premkumar of the Institute's Biological Chemistry Department and Prof. Joel Sussman and Dr. Harry Greenblatt of the Structur...

More>>

ADA in Biological Technology

Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS ), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presenta...

Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)

JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to display its abstract, entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin...

Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco

DENVER, June 4 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, is exhibiting its AspirinWorks(R) Test at the American Diabetes Association's 68th Scientific Sessions. The exhibits are open Saturday t...

Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced that the company will present new data for its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline diabetes and obe...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

... partially offset by increased clinical trial expenses. Recent Highlights Presentation of positive Phase 2 ZFP Therapeutic data at ada 2009. Sangamo announced the presentation of previously unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-5...

Data for SemBioSys' insulin to be presented at the American Diabetes Association's 69th Scientific Sessions

...ivalence of Recombinant Human Insulin from Transgenic Plants," by Joseph Boothe and colleagues. The abstract for the presentation is available via the ada website at http://ww2.aievolution.com/ada0901/index.cfm?do=abs.viewAbs&abs=7845 . The poster presentation details the clinical trial results of...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

...es Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009. ada : Ernest N. Morial Convention Center, New Orleans , LA. Saturday, June 6: Embargo Lifts June 6 at 9:00 a.m. CT Oral Presentatio...

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

..., D., Weiner, G., Denham, D. and Alessi, T. "We are very pleased the ada scientific reviewers selected our study for presentation as a late-breaker,...g a more complete analysis of 28-day results from all four dose arms at the ada Conference." ITCA 650 therapy in this phase 1 trial is administered fo...

Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products

... enhance the quality, safety and nutritional value of food. In its position statement published in the Journal of the American Dietetic Association , ada encourages the availability of these products in the marketplace. Consumers have long recognized soyfoods as healthy, as well. USB's Consumer ...

AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening

...first series of tests, we identified a life threatening condition in a local 16 year old, which on its own justifies our program. I plan to be back in ada to help raise awareness about heart disease and visit with the young man and his family." The Foundation is performing heart screening at its traile...

More>>